Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Voting Common Stock, par value $0.0001 per share
-
Shares outstanding
-
52,382,313
-
Number of holders
-
79
-
Total 13F shares, excl. options
-
35,724,879
-
Shares change
-
-4,382,817
-
Total reported value, excl. options
-
$51,820,655
-
Value change
-
-$5,881,550
-
Number of buys
-
46
-
Number of sells
-
-49
-
Price
-
$1.45
Significant Holders of TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) as of Q2 2025
112 filings reported holding TCRX - TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share as of Q2 2025.
TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) has 79 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35,724,879 shares
of 52,382,313 outstanding shares and own 68% of the company stock.
Largest 10 shareholders include Lynx1 Capital Management LP (7,857,347 shares), BVF INC/IL (5,226,074 shares), BAKER BROS. ADVISORS LP (2,784,792 shares), BlackRock, Inc. (2,566,524 shares), VANGUARD GROUP INC (2,149,376 shares), Propel Bio Management, LLC (2,087,139 shares), Deer Management Co. LLC (1,245,504 shares), Alphabet Inc. (1,077,080 shares), Simplify Asset Management Inc. (1,046,916 shares), and Aberdeen Group plc (891,448 shares).
This table shows the top 79 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.